By ICN GroupChemical, June 02, 2020
AGC acquires AstraZeneca's biopharma plant
AGC will prepare for the plant to resume full-scale operations by April 2021.
AGC Inc. has announced the purchase of a biopharmaceutical commercial manufacturing facility in Boulder, Colorado, USA. The facility, formerly owned by AstreaZeneca, will provide AGC with additional capacity and significantly larger production scale. AGC will prepare for the plant to resume full-scale operations by April 2021.
AGC Biologics, a U.S.-based CDMO subsidiary of the company, utilizes mammalian cells and microorganisms to provide a variety of high value-added services that range from process development to scale-up, and manufacturing of biopharmaceutical APIs. It’s contract base covers needs from early stage clinical trials through commercial manufacturing, with particular strength in its flexible single-use production lines fit for producing multiple products and products with volume volatility.
The Colorado facility is a large-scale biopharmaceutical manufacturing plant that houses two 20,000-liter (total volume) stainless steel mammalian cell bioreactors, and is well suited for higher volume commercial production. It also has more than twenty acres of land providing opportunities for future expansions. The existing plant has space for up to four more 20,000-liter bioreactors. With its expanded customer portfolio, as well as current projects advancing into commercial phase, AGC Biologics was looking to expand its footprint. This addition will enable AGC Biologics to support a wider range of commercial demand, and fulfill the needs of the pharmaceutical industry better.